Main Category: Multiple Sclerosis
Also Included In: Neurology / Neuroscience; Stem Cell Research
Article Date: 15 Apr 2013 - 2:00 PDT
New Technique Holds Promise For The Treatment Of Multiple Sclerosis And Cerebral Palsy
15 Apr 2013Researchers at Case Western Reserve School of Medicine have discovered a technique that directly converts skin cells to the type of brain cells destroyed in patients with multiple sclerosis, cerebral palsy and other so-called myelin disorders.
This discovery appears in the journal Nature Biotechnology.
This breakthrough now enables "on demand" production of myelinating cells, which provide a vital sheath of insulation that protects neurons and enables the delivery of brain impulses to the rest of the body.
In
patients with multiple sclerosis (MS), cerebral palsy (CP), and rare
genetic disorders called leukodystrophies, myelinating cells are
destroyed and cannot be replaced.
The new technique involves directly converting fibroblasts - an abundant structural cell present in the skin and most organs - into oligodendrocytes, the type of cell responsible for myelinating the neurons of the brain.
"Its 'cellular alchemy,'" explained Paul Tesar, PhD, assistant professor of genetics and genome sciences at Case Western Reserve School of Medicine and senior author of the study. "We are taking a readily accessible and abundant cell and completely switching its identity to become a highly valuable cell for therapy."
In a process termed "cellular reprogramming," researchers manipulated the levels of three naturally occurring proteins to induce fibroblast cells to become precursors to oligodendrocytes (called oligodendrocyte progenitor cells, or OPCs). Tesar's team, led by Case Western Reserve researchers and co-first authors Fadi Najm and Angela Lager, rapidly generated billions of these induced OPCs (called iOPCs).
The new technique involves directly converting fibroblasts - an abundant structural cell present in the skin and most organs - into oligodendrocytes, the type of cell responsible for myelinating the neurons of the brain.
"Its 'cellular alchemy,'" explained Paul Tesar, PhD, assistant professor of genetics and genome sciences at Case Western Reserve School of Medicine and senior author of the study. "We are taking a readily accessible and abundant cell and completely switching its identity to become a highly valuable cell for therapy."
In a process termed "cellular reprogramming," researchers manipulated the levels of three naturally occurring proteins to induce fibroblast cells to become precursors to oligodendrocytes (called oligodendrocyte progenitor cells, or OPCs). Tesar's team, led by Case Western Reserve researchers and co-first authors Fadi Najm and Angela Lager, rapidly generated billions of these induced OPCs (called iOPCs).
Even more important, they showed that iOPCs
could regenerate new myelin coatings around nerves after being
transplanted to mice - a result that offers hope the technique might be
used to treat human myelin disorders.
When oligodendrocytes are damaged or become dysfunctional in myelinating diseases, the insulating myelin coating that normally coats nerves is lost. A cure requires the myelin coating to be regenerated by replacement oligodendrocytes.
Until now, OPCs and oligodendrocytes could only be obtained from fetal tissue or pluripotent stem cells. These techniques have been valuable, but with limitations.
"The myelin repair field has been hampered by an inability to rapidly generate safe and effective sources of functional oligodendrocytes," explained co-author and myelin expert Robert Miller, PhD, professor of neurosciences at the Case Western Reserve School of Medicine and the university's vice president for research.
When oligodendrocytes are damaged or become dysfunctional in myelinating diseases, the insulating myelin coating that normally coats nerves is lost. A cure requires the myelin coating to be regenerated by replacement oligodendrocytes.
Until now, OPCs and oligodendrocytes could only be obtained from fetal tissue or pluripotent stem cells. These techniques have been valuable, but with limitations.
"The myelin repair field has been hampered by an inability to rapidly generate safe and effective sources of functional oligodendrocytes," explained co-author and myelin expert Robert Miller, PhD, professor of neurosciences at the Case Western Reserve School of Medicine and the university's vice president for research.
"The new technique may
overcome all of these issues by providing a rapid and streamlined way to
directly generate functional myelin producing cells."
This initial study used mouse cells. The critical next step is to demonstrate feasibility and safety using human cells in a lab setting. If successful, the technique could have widespread therapeutic application to human myelin disorders.
"The progression of stem cell biology is providing opportunities for clinical translation that a decade ago would not have been possible," said Stanton Gerson, MD, professor of Medicine-Hematology/Oncology at the School of Medicine and director of the National Center for Regenerative Medicine and the UH Case Medical Center Seidman Cancer Center.
This initial study used mouse cells. The critical next step is to demonstrate feasibility and safety using human cells in a lab setting. If successful, the technique could have widespread therapeutic application to human myelin disorders.
"The progression of stem cell biology is providing opportunities for clinical translation that a decade ago would not have been possible," said Stanton Gerson, MD, professor of Medicine-Hematology/Oncology at the School of Medicine and director of the National Center for Regenerative Medicine and the UH Case Medical Center Seidman Cancer Center.
"It is a real breakthrough."
References:
Additional co-authors of the publication include Case Western Reserve School of Medicine researchers Anita Zaremba, Krysta Wyatt, Andrew Caprariello, Daniel Factor, Robert Karl, and Tadao Maeda.
The research was supported by funding from the National Institutes of Health, the New York Stem Cell Foundation, the Mt. Sinai Health Care Foundation and Case Western Reserve University School of Medicine.
Case Western Reserve University
Citations:
Please use one of the following formats to cite this article in your essay, paper or report:
MLA
Case Western Reserve University. "New Technique Holds Promise For The Treatment Of Multiple Sclerosis And Cerebral Palsy." Medical News Today. MediLexicon, Intl., 15 Apr. 2013. Web.
16 Apr. 2013.
APA16 Apr. 2013.
Case Western Reserve University.
(2013, April 15). "New Technique Holds Promise For The Treatment Of
Multiple Sclerosis And Cerebral Palsy." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/259106.php.
http://www.medicalnewstoday.com/releases/259106.php.
Please note: If no author information is provided, the source is cited instead.
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Weekly newsletter e-mails available at: http://www.medicalnewstoday.com/newsletters.php
Send your press releases to
pressrelease@medicalnewstoday.com
Source: http://www.medicalnewstoday.com/releases/259106.php
MORE: Multiple sclerosis news:
http://www.medicalnewstoday.com/sections/multiple_sclerosis/
Source: http://www.medicalnewstoday.com/releases/259106.php
MORE: Multiple sclerosis news:
http://www.medicalnewstoday.com/sections/multiple_sclerosis/
No comments:
Post a Comment